Tag: RAPIDAI

RapidAI highlights TIMELESS trial publication among other key ISC 2024 presentations

RapidAI has announced the publication of TIMELESS—a randomised trial evaluating the use of tenecteplase in acute ischaemic stroke treatment—in the New England Journal of Medicine...

New UK NICE guidance endorses AI-derived software in stroke assessments

A new guidance document from the UK National Institute of Health and Care Excellence (NICE) has endorsed National Health Service (NHS) deployment of two...

RapidAI receives US FDA clearance of AI module for detecting hemispheric...

RapidAI announced today that it has received US Food and Drug Administration (FDA) clearance for Rapid SDH, its artificial intelligence (AI)-powered module for the detection...

RapidAI announces US$75 million growth investment led by Vista Credit Partners

RapidAI today announced US$75 million in Series C funding led by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on the...

RapidAI wins MedTech Breakthrough award for best new imaging solution

RapidAI announced recently that its combined haemorrhagic solution—Rapid ICH (intracranial haemorrhage) and Rapid Hyperdensity—has been selected as the “Best New Imaging Solution” in the...

RapidAI receives US FDA 510(k) clearance for new imaging product to...

RapidAI announced today that it has received US Food and Drug Administration (FDA) 510(k) clearance for Rapid non-contrast computed tomography (NCCT) Stroke, which is...

Brain Aneurysm Foundation welcomes Carolina Maier to its board of directors

The Brain Aneurysm Foundation (BAF), a leading global research and advocacy organisation committed to improving treatment and care for brain aneurysms, has announced the addition...

Rapid ICH receives new US FDA clearance with “highest sensitivity and...

RapidAI has announced receipt of US Food and Drug Administration (FDA) 510(k) clearance for the latest release of Rapid ICH—a technology that it describes as...

RAPID Aneurysm programme shows positive early performance in retrospective study

RAPID Aneurysm, a semi-automated artificial intelligence (AI) software programme (RapidAI), is highly accurate in detecting cerebral aneurysms on computed tomography angiography (CTA) imaging, according...

RapidAI receives US FDA clearance for Rapid Hyperdensity

RapidAI has announced receipt of US Food and Drug Administration (FDA) clearance for Rapid Hyperdensity—the newest addition to the RapidAI platform. According to the company,...

RapidAI announces Karim Karti as new CEO

RapidAI has announced Karim Karti, former president and CEO of GE Healthcare Imaging, as the company’s chief executive officer (CEO). “Karim’s tremendous global experience in...

RapidAI unveils prehospital solution to optimise cross-team workflow and improve patient...

RapidAI has announced the launch of its Rapid prehospital workflow solution for stroke, which optimises coordination between emergency medical services (EMS) providers and hospital...
rapidAI Rapid LVO FDA approval

RapidAI experiences nearly 300% growth

RapidAI, a neuroimaging stroke software platform which uses artificial intelligence (AI), has announced growth of nearly 300%. This has been attributed by RapidAI in...
rapidAI Rapid LVO FDA approval

RapidAI announces software approval for Medicare New Technology Add-on Payment

RapidAI states Rapid LVO is among the first software products to qualify for the New Technology Add-on Payment (NTAP). NTAP is part of the CMS...